Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin is a semisynthetic penicillin antibiotic in the aminopenicillin class of the penicillin family. It was first described in 1972 and approved by the FDA in 1974. Amoxicillin is used to treat a variety of bacterial infections including pneumonia, bronchitis, sinusitis, tonsillitis, ear infections (otitis media), urinary tract infections (UTIs), skin infections and as part of combination therapy for Helicobacter pylori-associated ulcers[1][2][4][5]. Its mechanism of action involves inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby preventing cross-linking of peptidoglycan chains essential for cell wall structural integrity. This leads to bacterial lysis and death[5][6][7]. Amoxicillin is effective against many gram-positive and some gram-negative bacteria but is not active against beta-lactamase-producing organisms unless combined with a beta-lactamase inhibitor such as clavulanate[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin.